Modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells
1Department of Central Laboratory, The Affiliated People's Hospital, Jiangsu University, Jiangsu, P.R. China.
Oncology Letters
|June 29, 2012
Summary
Triptolide reverses adriamycin resistance in leukemia cells by inhibiting P-glycoprotein expression and function. This enhances adriamycin accumulation, offering a potential strategy against multidrug resistance in leukemia treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Multidrug resistance (MDR) is a major challenge in leukemia therapy.
- Overexpression of the multidrug resistance gene 1 (MDR1) and its product P-glycoprotein is a primary cause of MDR in leukemia.
- Adriamycin resistance in K562/A02 cells is linked to MDR1.
Purpose of the Study:
- To investigate the effect of triptolide on P-glycoprotein expression and function in adriamycin-resistant K562/A02 leukemia cells.
- To determine if triptolide can reverse adriamycin resistance in these cells.
Main Methods:
- Cell viability was assessed using the MTT assay.
- Apoptosis was measured by Annexin V/FITC and propidium iodide staining.
- Intracellular adriamycin accumulation and P-glycoprotein expression were analyzed by flow cytometry.
- MDR1 promoter activity was evaluated using a luciferase reporter gene assay.
Main Results:
- Triptolide significantly reduced adriamycin resistance in K562/A02 cells.
- Triptolide inhibited P-glycoprotein expression and drug efflux, leading to increased intracellular adriamycin accumulation.
- Triptolide suppressed the transcriptional activity of the MDR1 promoter.
Conclusions:
- Triptolide effectively reverses adriamycin resistance in K562/A02 cells.
- Modulation of P-glycoprotein expression and function by triptolide is a key mechanism.
- Triptolide shows potential as a therapeutic agent to overcome multidrug resistance in leukemia.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:06Carrier-Mediated Transport
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...